IBISWorld Platform
Answer any industry question in minutes with our entire database at your fingertips.
In the last five years, turnover in the pharmaceutical industry has fallen by an average of 1.9% per year. Turnover did increase during the coronavirus pandemic, as the industry recorded stable demand at home and abroad and pharmaceutical supply chains remained intact despite pandemic-related shocks. Nevertheless, the pharmaceutical industry was exposed to high cost pressure in the years that followed. For example, chemical goods became massively more expensive in the wake of the energy crisis in 2022. The high prices for energy and primary products have driven up input costs even further in recent years. Procurement risks arose, among other things, from price increases and the lack of advance deliveries from the chemical industry, which cut back on production as a result of the high energy costs. The increased costs could not be passed on in full and had a negative impact on the profit margin. In addition to a decline in demand for vaccines, the economic policy framework, above all the SHI Financial Stabilisation Act, which came into force at the end of 2022 and increased the mandatory manufacturer discount for patented drugs from 7% to 12% for 2023, had a negative impact on the business of industry players.
Answer any industry question in minutes with our entire database at your fingertips.
Feed trusted, human-driven industry intelligence straight into your platform.
Streamline your workflow with IBISWorld’s intelligence built into your toolkit.
IBISWorld's research coverage on the Pharmaceutical Preparations Manufacturing industry in Germany includes market sizing, forecasting, data and analysis from 2015-2030. The most recent publication was released November 2025.
The Pharmaceutical Preparations Manufacturing industry in Germany operates under the WZ industry code C21.20DE. This sector is involved in the manufacture of medicines, vaccines, various pharmaceuticals and homeopathic products. This also includes chemical contraceptives, radioactive substances for in vivo diagnostics and biotechnological products. In addition, there is the production of dressing materials and the preparation of botanical materials for further processing in the pharmaceutical sector. Related terms covered in the Pharmaceutical Preparations Manufacturing industry in Germany include biopharmaceuticals/biologics, biosimilars, otc drugs, bioinformatics, generica and homeopathy.
Products and services covered in Pharmaceutical Preparations Manufacturing industry in Germany include Medicines without antibiotics or hormones, Medication from antibiotics and Antisera, vaccines and other blood components.
Companies covered in the Pharmaceutical Preparations Manufacturing industry in Germany include F. Hoffmann-La Roche AG, Boehringer Ingelheim Pharma GmbH & Co. KG and Bayer AG.
The Performance chapter covers detailed analysis, datasets, detailed current performance, sources of volatility and an outlook with forecasts for the Pharmaceutical Preparations Manufacturing industry in Germany.
Questions answered in this chapter include what's driving current industry performance, what influences industry volatility, how do successful businesses overcome volatility, what's driving the industry outlook. This analysis is supported with data and statistics on industry revenues, costs, profits, businesses and employees.
The Products and Markets chapter covers detailed product and service segmentation, analysis of major markets and international trade data for the for the Pharmaceutical Preparations Manufacturing industry in Germany.
Questions answered in this chapter include how are the industry's products and services performing, what are innovations in industry products and services, what products or services do successful businesses offer and what's influencing demand from the industry's markets. This includes data and statistics on industry revenues by product and service segmentation and major markets.
The Geographic Breakdown chapter covers detailed analysis and datasets on regional performance of the Pharmaceutical Preparations Manufacturing industry in Germany.
Questions answered in this chapter include where are industry businesses located and how do businesses use location to their advantage. This includes data and statistics on industry revenues by location.
The Competitive Forces chapter covers the concentration, barriers to entry and supplier and buyer profiles in the Pharmaceutical Preparations Manufacturing industry in Germany. This includes data and statistics on industry market share concentration, barriers to entry, substitute products and buyer & supplier power.
Questions answered in this chapter include what impacts the industry's market share concentration, how do successful businesses handle concentration, what challenges do potential industry entrants face, how can potential entrants overcome barriers to entry, what are substitutes for industry services, how do successful businesses compete with substitutes and what power do buyers and suppliers have over the industry and how do successful businesses manage buyer & supplier power.
The Companies chapter covers Key Takeaways, Market Share and Companies in the Pharmaceutical Preparations Manufacturing industry in Germany. This includes data and analysis on companies operating in the industry that hold a market share greater than 5%.
Questions answered in this chapter include what companies have a meaningful market share and how each company is performing.
The External Environment chapter covers Key Takeaways, External Drivers, Regulation & Policy and Assistance in the Pharmaceutical Preparations Manufacturing industry in Germany. This includes data and statistics on factors impacting industry revenue such as economic indicators, regulation, policy and assistance programs.
Questions answered in this chapter include what demographic and macroeconomic factors impact the industry, what regulations impact the industry, what assistance is available to this industry.
The Financial Benchmarks chapter covers Key Takeaways, Cost Structure, Financial Ratios, Valuation Multiples and Key Ratios in the Pharmaceutical Preparations Manufacturing industry in Germany. This includes financial data and statistics on industry performance including key cost inputs, profitability, key financial ratios and enterprise value multiples.
Questions answered in this chapter include what trends impact industry costs and how financial ratios have changed overtime.
The Industry Data chapter includes 10 years of historical data with 5 years of forecast data covering statistics like revenue, industry value add, establishments, enterprises, employment and wages in the Pharmaceutical Preparations Manufacturing industry in Germany.
More than 6,000 businesses use IBISWorld to shape local and global economies
We were able to supplement our reports with IBISWorld’s information from both a qualitative and quantitative standpoint. All of our reporting now features some level of IBISWorld integration.
IBISWorld delivers the crisp business knowledge we need to drive our business. Whether it be serving up our major clients, winning new business or educating on industry issues, IBISWorld brings real value.
IBISWorld has revolutionised business information — which has proved commercially invaluable to exporters, investors and public policy professionals in Australia and overseas.
When you’re able to speak to clients and be knowledgeable about what they do and the state that they operate in, they’re going to trust you a lot more.
The market size of the Pharmaceutical Preparations Manufacturing industry in Germany is €95.5bn in 2026.
There are 580 businesses in the Pharmaceutical Preparations Manufacturing industry in Germany, which has declined at a CAGR of 0.2 % between 2020 and 2025.
The Pharmaceutical Preparations Manufacturing industry in Germany is likely to be significantly impacted by import tariffs with imports accounting for a high share of industry revenue.
The Pharmaceutical Preparations Manufacturing industry in Germany is likely to be significantly impacted by export tariffs with exports accounting for a high share of industry revenue.
The market size of the Pharmaceutical Preparations Manufacturing industry in Germany has been declining at a CAGR of 1.9 % between 2020 and 2025.
Over the next five years, the Pharmaceutical Preparations Manufacturing industry in Germany is expected to grow.
The biggest companies operating in the Pharmaceutical Preparations Manufacturing industry in Germany are F. Hoffmann-La Roche AG, Boehringer Ingelheim Pharma GmbH & Co. KG and Bayer AG
Medicines without antibiotics or hormones and Medication from antibiotics are part of the Pharmaceutical Preparations Manufacturing industry in Germany.
The company holding the most market share in the Pharmaceutical Preparations Manufacturing industry in Germany is F. Hoffmann-La Roche AG.